European Regional Development Fund ERDF Cell and Gene Therapy Catapult

Manufacturing centre, Stevenage, UK

To help support the growing industry, we have built a large-scale GMP manufacturing centre, which through collaborations, will help address the manufacturing challenges faced by therapy developers.

 

The centre supports the development of new large-scale manufacturing systems and capabilities, helping you to bring your cell and gene therapies to market.

Cell and Gene Therapy Catapult manufacturing centre virtual tour

Take a virtual tour of the Stevenage centre in this video

The Cell and Gene Therapy Catapult manufacturing centre provides you with the supported environment to develop your large-scale manufacturing systems, whilst segregated modules allow you to maintain control of your underlying process.

The licensed GMP-compliant manufacturing centre provides you with the flexibility of your own facility, as well as access to an established supply chain.

Benefits

1. Ready when you need it

Through collaborations we support you to develop new large-scale manufacturing systems, without the need for capital investment or the associated risk of building and licensing your own facility.

The centre can offer the opportunity for acceleration of commercial-scale production.

2. Access established supply chain

The centre’s location enables you to access an established international in-bound supply chain, to support your manufacture. The effective outbound supply chain, with its easy access to Heathrow and major international transport links, also allows you to receive and deliver your therapies to key clinical centres.

The Fisher BioServices’ CryoHub located at the centre provides a complete cryogenic storage, distribution and logistics solution.

3. Flexible to your needs

The centre is designed to be adaptable to your processing needs, enabling you to flex to your manufacturing strategy and as you grow, take on more modules or replicate your module design in your own facility.

The flexible module design and supporting infrastructure is adaptable to your own process, whether it is allogenic, viral vector or autologous.

4. Control your manufacturing strategy

The centre’s architecturally segregated modules allow you to develop your process while retaining your intellectual property (IP) and know how. The people, process, quality management system, batch release and IP are all yours.

We will work with you, managing core operational and quality assurance activities, letting you focus on developing your processes.

5. Collaborate with industry specialists

The centre is supported by a team of specialists across the cell and gene therapy lifecycle, who will work with you when you need them.

Floor plan

The centre has been specifically designed to meet the demands of cell and gene therapy manufacturing. The adaptable clean room design will allow the development of autologous or allogenic manufacturing processes, as well as viral vectors.

 

Expansion phase

In July 2018 CGT Catapult was awarded £3.36m in funding from the European Regional Development Fund (ERDF) to support the construction of the expansion of the manufacturing centre and to provide additional support to growing cell and gene therapy companies. The expansion involves the construction of six additional modules in the already constructed space on the building's second floor.

The six additional modules will contain grade C cleanrooms and each will have a production footprint of 130m2. The additional space and support for this project will allow CGT Catapult to engage further with UK businesses and help them progress towards commercialisation.

Commercial readiness advice clinics

Core to our mission is assisting companies to accelerate their product from research status into a viable commercial product. Our commercial readiness advice clinics allow eligible spin-out companies and SMEs to benefit from 12 hours of tailored support in preparation for industrialisation. The commercial readiness advice clinics provide access to CGT Catapult experts from all steps of product development including: clinical,

This programme is part funded by the European Regional Development Fund (ERDF).

The Stevenage cluster

Click and drag to explore the Stevenage cluster in the interactive map below:

 

This unique new centre will bring together our expertise in medicines manufacturing with our world-beating science and research base to create revolutionary treatments that fight diseases like cancer and save lives. 

Rt Hon Greg Clark MP, Secretary of State for Business, Energy and Industrial Strategy

This new cell and gene centre represents our ambitious Industrial Strategy in action. By bringing together universities and businesses we can not only create the high value jobs we need but also develop potentially lifesaving treatments. 

Sam Gyimah MP, Minister of State for Universities, Science, Research and Innovation

The Cell and Gene Therapy Catapult manufacturing centre is a crucial component of the industrial strategy and part of the leading-edge healthcare technology challenge fund. This world-leading centre will bring manufacturing of pioneering treatments closer to patients and will complement the new Advanced Therapy Treatment Centres. 

Dr Ian Campbell, Interim Executive-Chair, Innovate UK

European Regional Development Fund

The project has received £3.36m of funding from the England European Regional Development Fund as part of the European Structural and Investment Funds Growth Programme 2014-2020. The Ministry of Housing, Communities and Local Government (and in London the intermediate body Greater London Authority) is the Managing Authority for European Regional Development Fund. Established by the European Union, the European Regional Development Fund helps local areas stimulate their economic development by investing in projects which will support innovation, businesses, create jobs and local community regenerations. For more information visit https://www.gov.uk/european-growth-funding.

Related Publications

23 October 2019
pdf
Development of a scalable platform for AAV manufacturing
Adrien Soula & Juline Guenat
22 October 2019
pdf
ATMP Project - Perspectives on preparedness: healthcare system readiness for adoption of disruptive innovative technologies
Claire Foreman, Head of Acute Programmes, NHS England
16 July 2019
webpage
Annual Review 2019
Cell and Gene Therapy Catapult

Discover who we are